GlassScriptPhysician profile
Norman A Leopold
NPI 1740341569
$2,357.97
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,941 · 2020: $417.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $574.83 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $208.48 | 2019 | |
| Sunovion Pharmaceuticals INC. | $173.06 | 2019-2020 | |
| Genzyme Corporation | $124.98 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $118.81 | 2019-2020 | |
| Biogen, INC. | $109.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.82 | 2019-2020 | |
| Ucb, INC. | $95.97 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $94.64 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $88.80 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $82.40 | 2019 | |
| Adamas Pharmaceuticals, INC. | $82.37 | 2019 | |
| Emd Serono, INC. | $79.00 | 2019 | |
| Acorda Therapeutics, INC | $68.96 | 2019 | |
| Grifols USA, LLC | $44.80 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $44.72 | 2019-2020 | |
| Lundbeck LLC | $44.01 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $28.36 | 2019 | |
| Merz North America, INC. | $27.56 | 2019 | |
| Akcea Therapeutics, INC. | $25.32 | 2019 | |
| Celgene Corporation | $23.52 | 2019 | |
| Bausch Health US, LLC | $23.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.73 | 2019 | |
| Genentech USA, INC. | $19.33 | 2019 | |
| Lilly USA, LLC | $18.77 | 2019 | |
| Eisai INC. | $16.35 | 2019 | |
| Tanabe Pharma America, INC. | $13.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Leopold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.